secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001640334-26-000662
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences regains Nasdaq compliance; monitored for one year
--------------------------------------------------------------------

- Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.
- Subject to mandatory panel monitor through April 6, 2027; re-deficiency could trigger delisting.
- CEO cites focus on ART27.13 (cancer cachexia) Phase 2 data, ART26.12 (neuropathic pain), and partnerships.
- Common stock trades on Nasdaq under ticker ARTL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/0001640334-26-000662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-000662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer